Voyager nears clinical trials for Alzheimer’s after robust safety data
Voyager Therapeutics (NASDAQ:VYGR) achieved a critical regulatory milestone this week, presenting positive three-month toxicology data for its lead Alzheimer’s disease candidate, VY1706.
In a late-breaking presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, the company confirmed that a single intravenous dose of the tau-silencing gene therapy was well tolerated in non-human primates.
Notably, the treatment achieved a 64% reduction in tau protein within key brain regions, reinforcing the potential of Voyager’s TRACER™ capsid platform to deliver genetic medicine across the blood-brain barrier.
The company remains on a strict timeline for clinical entry, with an Investigational New Drug (IND) application for VY1706 expected to be submitted to the FDA by the end of second quarter 2026.
This schedule supports the company's projection for first-in-human dosing in the second half of the year.
Beyond its lead program, Voyager showcased the versatility of its platform at ASGCT, highlighting "stealth" capsids designed to evade human neutralizing antibodies and novel variants that achieved 100X higher muscle expression than standard AAV9 models in preclinical studies.
Financially, Voyager entered the second quarter in a stable position, reporting first-quarter 2026 results that surpassed analyst expectations on the bottom line.
The company posted a net loss of $27.9 million, or $0.47 per share, beating the consensus estimate of a $0.54 loss.
While quarterly revenue of $1.19 million fell short of expectations due to the timing of collaboration milestones, the firm’s disciplined cost-cutting initiatives reduced research and development expenses to $24.6 million for the quarter.
The company concluded the period with $171.7 million in cash, cash equivalents, and marketable securities.
According to management, this capital provides a financial runway into 2028, covering the critical window for initial clinical data readouts for VY1706 and its anti-tau antibody program, VY7523.